ESCRS 2023: Integrated workflow solutions in cataract procedures

News
Video

Euan Thomson, the President of Ophthalmic Devices, Carl Zeiss Meditec spoke with our team about integrated workflow solutions and how they can benefit cataract procedures while at the 2023 ESCRS meeting in Vienna, Austria.

Euan Thomson, the President of Ophthalmic Devices, Carl Zeiss Meditec spoke with our team about integrated workflow solutions and how they can benefit cataract procedures while at the 2023 ESCRS meeting in Vienna, Austria.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Euan Thomson: So I'm Euan Thompson, I'm President of Ophthalmology at Carl Zeiss, and Head of Digital Business. You know, we're working very hard on creating integrated workflow solutions. This is a big theme for us. And I think that, as people go around our booth, there's actually going to be a high level of integration that we've already been able to achieve.

Some of our workflows are complete; cataract workflow, for example, is there. And we've actually been able to demonstrate the value of this to customers. So we're really targeting new value propositions beyond the technology itself. We're really looking at efficiency gains in the operating room efficiency gains in the run up to a treatment. We're looking at quality improvement, standardization, and we're actually already gathering data on these. So we're really excited about that and really looking forward to showcasing it today.

So what I'm looking forward to in 2024, is really, really demonstrating the power of the level of integration that we've achieved, you know, our digitally connected workflows are really quite evolved now. The true value of those in terms of, you know, the efficiency gains and standardization and so on these new value propositions, being able to test those and getting the data back is really exciting, you know. A cataract workflow, we've actually now got demonstrable data that shows that there is a true efficiency gain, not just in the run up to a treatment but in the operating room itself. And it can be as high as 30% timesaving in the operating room for some procedures. So this is meaningful improvements in the standard of care.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.